LONDON, Nov. 2, 2016 /PRNewswire/ --
In a newly published report on Polycystic Ovary Syndrome (PCOS) Drugs, Persistence Market Research analyzes the PCOS drugs market over an eight-year period from 2016 to 2024 and studies the key drivers and trends impacting the market. The primary objective of the report is to provide updates and information related to market opportunities and useful insights into factors that are significantly transforming businesses and enterprises in the global PCOS market.
Polycystic ovary syndrome (PCOS) – also known as Stein-Leventhal Syndrome – is a common hormonal endocrine disorder that affects women of child bearing age i.e. 15 to 49 years. This disease is characterized by the formation of cysts on the ovaries leading to an insufficiency of the ovulation initiating hormone in the female body. PCOS mainly occurs due to a combination of environmental and genetic factors, which cause an abnormal function of the hormones present in the pituitary gland that regulate ovulation. Few of the symptoms of PCOS include irregular menstruation, excess facial and body hair, infertility, and acne and other skin problems. PCOS is also associated with diseases such as type 2 diabetes, obesity, heart diseases, acute depression, and obstructive sleep apnea.
Currently, there are no specific diagnostic tests available for the detection of PCOS; however, blood tests, physical examination, vaginal ultrasound, and medical history analysis are widely recommended by general physicians and gynecologists. While there is no cure for PCOS, its symptoms and associated conditions can be managed with the help of lifestyle modification activities, weight loss management, and medications. Currently, no drugs are approved by the FDA and EMA for PCOS. However, oral contraceptives, insulin sensitizing agents, and aromatase inhibitors are used as first line agents for the treatment of irregular menstruation, diabetes, and facial hair growth respectively.
This report covers the global PCOS drugs market performance in terms of revenue contribution from various segments. Included in the report is a detailed impact analysis of key trends, drivers, restraints, and opportunities influencing the growth of the global polycystic ovary syndrome drugs market. The report begins with an overview of the polycystic ovary syndrome drugs process and the main reasons why patients worldwide are adopting this process. This section also underlines factors influencing the growth of the global polycystic ovary syndrome drugs market along with detailing of the key trends, drivers, restraints, opportunities, and regulations. The report also provides strategic recommendations for key players in the market to strengthen their footprint and ensure their business stays sustainably profitable.
The next few sections provide a detailed analysis for every segment and sub-segment of the global PCOS drugs market in terms of market size, Y-o-Y growth rate, absolute $ opportunity, market Attractiveness Index, and BPS analysis. The report further highlights the growth trends of the polycystic ovary syndrome drugs market by region and presents a market outlook for 2016–2024 – showcasing key regional trends contributing to the growth of the polycystic ovary syndrome drugs market worldwide, as well as an analysis into the extent to which drivers are influencing this market in each region.
The final section of the report includes detailed company profiles with company-specific long-term and short-term strategies, key offerings, and recent developments in the polycystic ovary syndrome drugs market. Some of the leading companies profiled in the report are Sanofi, Novartis, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck KGaA, and AstraZeneca Plc.
The report considers 2015 as the base year and provides data for the forecast period 2016–2024. To deduce market size, the report considers various viewpoints based on extensive primary and secondary research. The report begins by sizing the current market – a key indicator of how the market is likely to grow during the forecast period. Given the characteristics of the market, the report presents triangulated data on the basis of supply side and demand side analysis and other dynamics of the global polycystic ovary syndrome market. Key indicators such as number of PCOS patients in each year, adoption of treatment, diagnosis rate, etc., have been considered to arrive at the indicated market numbers.
Download the full report: https://www.reportbuyer.com/product/4257225/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Research Advisor at Reportbuyer.com
Tel: +44 208 816 85 48
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-market-study-on-polycystic-ovary-syndrome-pcos-treatment-north-america-likely-to-emerge-as-the-dominant-market-in-2016-300356452.html